The study reported the following rates of recurrent basal cell carcinoma (BCC) per 100 person-years: 34.5 for those on active thiopurine therapy, 17.8 for those on anti-TNF therapy alone, and 22.4 for patients receiving combined active thiopurine and anti-TNF therapy [17]. Here, TNF is linked to skin basal cell carcinoma.